JP2024538751A - 優れた適応免疫細胞の集団を促進することによる養子細胞移入の増強 - Google Patents

優れた適応免疫細胞の集団を促進することによる養子細胞移入の増強 Download PDF

Info

Publication number
JP2024538751A
JP2024538751A JP2024521318A JP2024521318A JP2024538751A JP 2024538751 A JP2024538751 A JP 2024538751A JP 2024521318 A JP2024521318 A JP 2024521318A JP 2024521318 A JP2024521318 A JP 2024521318A JP 2024538751 A JP2024538751 A JP 2024538751A
Authority
JP
Japan
Prior art keywords
cells
cell
mitochondria
immune
immune cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538751A5 (enExample
Inventor
ドゥマウティオズ，ニナ
Original Assignee
セルヴィエ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルヴィエ インク． filed Critical セルヴィエ インク．
Publication of JP2024538751A publication Critical patent/JP2024538751A/ja
Publication of JP2024538751A5 publication Critical patent/JP2024538751A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2024521318A 2021-10-06 2022-10-06 優れた適応免疫細胞の集団を促進することによる養子細胞移入の増強 Pending JP2024538751A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253058P 2021-10-06 2021-10-06
US63/253,058 2021-10-06
PCT/US2022/077721 WO2023060212A1 (en) 2021-10-06 2022-10-06 Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells

Publications (2)

Publication Number Publication Date
JP2024538751A true JP2024538751A (ja) 2024-10-23
JP2024538751A5 JP2024538751A5 (enExample) 2025-10-15

Family

ID=83996498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521318A Pending JP2024538751A (ja) 2021-10-06 2022-10-06 優れた適応免疫細胞の集団を促進することによる養子細胞移入の増強

Country Status (7)

Country Link
US (1) US20240398950A1 (enExample)
EP (1) EP4412627A1 (enExample)
JP (1) JP2024538751A (enExample)
CN (1) CN118541160A (enExample)
AU (1) AU2022361057A1 (enExample)
CA (1) CA3233989A1 (enExample)
WO (1) WO2023060212A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4565684A1 (en) * 2022-08-02 2025-06-11 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes
JP2026523341A (ja) 2023-05-15 2026-07-14 エヌクロマ・バイオ，インコーポレーテッド Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
JP2017535284A (ja) * 2014-11-05 2017-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
WO2020036973A1 (en) * 2018-08-14 2020-02-20 Imel Biotherapeutics, Inc. Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
WO2020102321A1 (en) * 2018-11-13 2020-05-22 Abraham J And Phyllis Katz Cord Blood Foundation T cells with improved mitochondrial function
US20200181578A1 (en) * 2018-10-09 2020-06-11 The Regents Of The University Of California Mitochondrial transplantation to alter energy metabolism
WO2021199040A1 (en) * 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof
JP2023519744A (ja) * 2020-03-31 2023-05-12 ミノヴィア セラビューティクス リミテッド ミトコンドリア増強療法
JP2024525933A (ja) * 2021-05-18 2024-07-12 イメル バイオセラピューティクス， インコーポレイテッド ミトコンドリア置換を使用して免疫細胞疲弊を低減させるための方法および組成物
JP2024525941A (ja) * 2021-05-18 2024-07-12 イメル バイオセラピューティクス， インコーポレイテッド ミトコンドリア置換リンパ球系細胞を生成するための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
CA2952121A1 (en) 2014-06-13 2015-12-17 Childrens' Medical Center Corporation Products and methods to isolate mitochondria
CN109983120A (zh) * 2016-11-14 2019-07-05 白雁生物技术公司 含有外源线粒体的天然杀伤细胞和含有其的药物组合物
AU2021246112A1 (en) * 2020-04-03 2022-11-10 Cellvie Inc. Enhancement of adoptive cell transfer

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
JP2017535284A (ja) * 2014-11-05 2017-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
WO2020036973A1 (en) * 2018-08-14 2020-02-20 Imel Biotherapeutics, Inc. Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
US20200181578A1 (en) * 2018-10-09 2020-06-11 The Regents Of The University Of California Mitochondrial transplantation to alter energy metabolism
WO2020102321A1 (en) * 2018-11-13 2020-05-22 Abraham J And Phyllis Katz Cord Blood Foundation T cells with improved mitochondrial function
WO2021199040A1 (en) * 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof
JP2023519744A (ja) * 2020-03-31 2023-05-12 ミノヴィア セラビューティクス リミテッド ミトコンドリア増強療法
JP2024525933A (ja) * 2021-05-18 2024-07-12 イメル バイオセラピューティクス， インコーポレイテッド ミトコンドリア置換を使用して免疫細胞疲弊を低減させるための方法および組成物
JP2024525941A (ja) * 2021-05-18 2024-07-12 イメル バイオセラピューティクス， インコーポレイテッド ミトコンドリア置換リンパ球系細胞を生成するための方法および組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BMC BIOTECHNOLOGY, vol. Vol. 19, No. 1, Article No. 42, JPN5025008013, 2019, pages 1 - 14, ISSN: 0005889720 *
EMBO REPORTS, vol. Vol. 21, No. 2, Article No. e48052, JPN5025008010, 2020, pages 1 - 17, ISSN: 0005889719 *
FRONT. IMMUNOL., vol. Vol. 11, Article 1834, JPN6026025930, 2020, pages 1 - 8, ISSN: 0005889721 *

Also Published As

Publication number Publication date
US20240398950A1 (en) 2024-12-05
AU2022361057A1 (en) 2024-05-02
WO2023060212A1 (en) 2023-04-13
CA3233989A1 (en) 2023-04-13
EP4412627A1 (en) 2024-08-14
CN118541160A (zh) 2024-08-23

Similar Documents

Publication Publication Date Title
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
CN111247242B (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
JP6422134B2 (ja) キメラ抗原受容体
EP2970426B1 (en) Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
ES2963718T3 (es) Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
CN111479917A (zh) 经基因修饰以消除T细胞受体和β2-微球蛋白表达的永生化CAR-T细胞
JP2017535284A (ja) 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
US20240052310A1 (en) Enhancement of adoptive cell transfer
WO2023280307A1 (en) Mutant il-15 compositions and methods thereof
CN110352197B (zh) 嵌合氯毒素受体
WO2022037562A1 (en) Engineered immunoresponsive cells and uses thereof
EP4019538A1 (en) Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes
US20240398950A1 (en) Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells
WO2020140973A1 (en) Modified immune cells expressing flagellin polypeptide
CN117580870A (zh) 表达tlr受体的经修饰的免疫细胞
US20240108651A1 (en) Desmoglein 2-directed chimeric antigen receptor (CAR) constructs and methods of use
JP2021532814A (ja) Ｈａ−１特異的ｔ細胞受容体およびその使用
WO2024193714A1 (zh) 细胞免疫疗法的组合物和方法
HK40115153A (en) Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells
Rostami et al. Adoptive Immune Cell Therapy in Pediatric Solid Tumors
HK40093031A (en) Enhancement of adoptive cell transfer
EP4353253A1 (en) Purification of tcr-modified t cells using tcr-specific car-nk cells
WO2026062661A1 (en) A novel platform for the generation of "naive-like" cells of the t lineage and uses thereof
HK40105414A (en) Mutant il-15 compositions and methods thereof
WO2024233970A2 (en) Enrichment and expansion of chimeric antigen receptor t cells using antigen-presenting biomaterials

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260622